SAB Biotherapeutics rises after H.C.Wainwright initiates with 'buy' rating

SAB Biotherapeutics

29/11/2022 16:31

** Shares of drug developer SAB Biotherapeutics Inc  SABS.O 
rise ~5.7% to $1.11
    ** Brokerage H.C. Wainwright & Co initiates coverage with
"buy" rating on SABS' polyclonal antibody pipeline; sets PT of
$4
    ** Says company's technology platform, DiversitAb, is
designed to produce a new class of specifically targeted,
high-potency, fully human polyclonal antibodies without the need
for human donors
    ** Brokerage sees 2027 launch for SABS' influenza therapy
SAB-176, with sales of $12.5 million in 2027 and $290 million in
2030
    ** Expects 2029 launch for its treatment for clostridioides
difficile infection, SAB-195, which causes gastrointestinal
symptoms such as diarrhea, with sales of $75 million in 2029 and
$150 million in 2030 - H.C. Wainwright
    ** Polyclonal antibodies are a complex mixture of several
antibodies that are usually produced by different B-cell clones
of an animal 
    ** Stock down ~86% YTD vs ~11% decline in the Nasdaq
biotechnology index  .NBI 
 (Reporting by Sriparna Roy)
 ((Sriparna.roy@thomsonreuters.com))